

AGN 194310

Catalog No: tcsc3200



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg



Specifications

CAS No:

229961-45-9

Formula:

$C_{28}H_{24}O_2S$

Pathway:

Metabolic Enzyme/Protease

Target:

RAR/RXR

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

VTP-194310

Observed Molecular Weight:

424.55

Product Description


AGN 194310(VTP-194310) is a potent and selective pan-RARs agonist with K_d values of 3/2/5 nM for RAR α / β / γ respectively.

IC₅₀ value: 3/2/5 nM (K_d for RAR α / β / γ) [1][2]

Target: RARs agonist

in vitro: A high affinity pan-RAR antagonist (AGN194310, K_d for binding to RARs = 2-5 nM) inhibited colony formation (by 50%) by all three lines at 16-34 nM, and led to a transient accumulation of flask-cultured cells in G1 followed by apoptosis. AGN194310 is 12-22 fold more potent than all-trans retinoic acid (ATRA) against cell lines and also more potent in inhibiting the growth of primary prostate carcinoma cells [2].

in vivo: The administration of all-trans retinoic acid to VAD mice resulted in a transient reduction in NF-kappaB activity and, conversely, a single dose of the RAR-pan-antagonist, AGN 194310, administered to control mice, led to a marked, transient induction of whole-body luminescence [3]. Mice were treated with AGN194310, a synthetic retinoid that antagonises the physiological function of the three RAR isotypes (alpha, beta, gamma) but does not interact with RXRs. Analyses of the granulocytic lineage using Gr-1, c-Kit and CD11b antibodies, demonstrated that granulocyte numbers were strikingly increased across haemopoietic compartments in all AGN194310-treated mice. A significant increase in the frequency of progenitor cells containing granulocytes was observed in the bone marrow of mice following treatment with AGN194310 [4].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!